NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Theratechnologies Inc.
https://rdinvesting.com/news/?ticker=TH.TO

Microbix Biosystems Inc.
https://rdinvesting.com/news/?ticker=MBX.TO

Aeterna Zentaris Inc.
https://rdinvesting.com/news/?ticker=AEZS.TO

Neptune Technologies & Bioressources Inc.
https://rdinvesting.com/news/?ticker=NEPT.TO

Theratechnologies' stock moved 1.51% lower Monday, to close the day at $9.79. The stock recorded a trading volume of 381,402 shares, which was above its three months average volume of 138,200 shares. In the last year, Theratechnologies' shares have traded in a range of 4.91 - 10.05. The share price has gained 99.39% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $7.63 is greater than its 200-day moving average of $7.48. Shares of Theratechnologies have gained approximately 36.35 percent year-to-date.

Access RDI's Theratechnologies Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TH.TO

On Monday, shares of Microbix Biosystems recorded a trading volume of 2,000 shares, which was below the three months average volume of 48,383 shares. The stock ended the day 3.45% higher at 0.30. The share price has gained 36.36% from its 52 week low with a 52 week trading range of 0.22 - 0.40. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.29 is below its 200-day moving average of $0.32. Shares of Microbix Biosystems have fallen approximately 1.64 percent year-to-date.

Access RDI's Microbix Biosystems Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MBX.TO

Aeterna Zentaris' stock moved 1.82% lower Monday, to close the day at $2.16. The stock recorded a trading volume of 1,784 shares, which was below its three months average volume of 38,161 shares. In the last year, Aeterna Zentaris' shares have traded in a range of 1.10 - 5.06. The share price has gained 96.36% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.49 is below its 200-day moving average of $2.58. Shares of Aeterna Zentaris have fallen approximately 27.52 percent year-to-date.

Access RDI's Aeterna Zentaris Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AEZS.TO

On Monday, shares of Neptune Technologies & Bioressources recorded a trading volume of 67,202 shares, which was below the three months average volume of 288,753 shares. The stock ended the day 1.58% lower at 3.74. The share price has gained 334.88% from its 52 week low with a 52 week trading range of 0.86 - 4.41. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.76 is greater than its 200-day moving average of $2.27. Shares of the company are trading at a Price to Earnings ratio of 45.61. Shares of Neptune Technologies & Bioressources have gained approximately 26.35 percent year-to-date.

Access RDI's Neptune Technologies & Bioressources Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NEPT.TO

Our Actionable Research on Theratechnologies Inc. (TSX:TH.TO), Microbix Biosystems Inc. (TSX:MBX.TO), Aeterna Zentaris Inc. (TSX:AEZS.TO) and Neptune Technologies & Bioressources Inc. (TSX:NEPT.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com